Impact Factor
3.77
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.28
935 total citations
h5-index
39
h5 depth signal
Cited share
77.7%
174 of 224
Total citations
935
Citation footprint
Metric signal
4.01
External metric anchor
Self-citation
4.5%
42 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
576
China
251
Germany
131
United Kingdom
95
France
71
Citing Fields of Research
Viral Identification & Phylogenetics
457
Stem Cell Biology
197
Immunology
186
Genetics & Genomics
179
Immunotherapy
151
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
5,895
Articles tracked across the journal lifetime
Indexed publication set
224
174 cited publications
Last 12 months
134
11.2 publications/month
Open access share
11.2%
15 OA publications in the last year
Leading citing country
United States
576 citing publications
Leading citing field
Viral Identification & Phylogenetics
457 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v1n1,spring 1990-
v1n1,spring 1990-
Active Coverage
Research Focus & Classification
Indexed Subjects
Viral Identification & Phylogenetics
Genetics & Genomics
Lysosomal Storage Disorders
Musculoskeletal Disorders
Immunology
Cystic Fibrosis
Broad Categories
Genetics, Medical
Therapeutics
Viral Identification & Phylogenetics
MeSH Descriptors
Genetic Therapy
Transfection
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/10430342261495296
Open DOI
Complement Activation Within Minutes Following Systemic Administration of AAV in the Presence of AAV Immunity
A challenge of adeno-associated virus (AAV)–mediated gene therapy is the high prevalence of preexisting anticapsid antibodies, which can reduce vector efficacy and, after high-dose systemic administration, promote formation of antibody–v...
02
DOI 10.1177/10430342261495300
Open DOI
Ocular Gene Therapy in China: Technological Framework, Clinical Translation, and Future Perspectives
The eye is well suited to gene therapy because of its compartmentalized anatomy, accessibility for local delivery, and capacity for longitudinal assessment. In China, ocular gene therapy is undergoing rapid clinical translation, with exp...
03
DOI 10.1177/10430342261493722
Open DOI
Beyond Viruses: Transposons and CRISPR-Programmable Nonviral Systems for Genome Engineering
Human gene therapy has been transformed by repurposing mobile genetic elements as tools for efficient gene delivery and precise genome modification. Viruses, transposons, and retrotransposons mobilize genetic material through distinct me...
04
DOI 10.1177/10430342261492461
Open DOI
Automated Production of Gene-Edited CAR-T Cells for People Living with HIV
Adoptive transfer of gene-modified autologous T cells, for example, expressing chimeric antigen receptors (CARs), is a promising therapy option for a variety of malignant and nonmalignant diseases. Given their increased risk to develop c...
05
06
DOI 10.1177/10430342261490050
Open DOI
Regulatory Progress in the Clinical Translation of Gene Therapy in China: Evolution, Challenges, and Future Perspectives
In recent years, gene therapy has emerged as a major frontier in biomedicine, with translation from basic research to clinical application accelerating worldwide. Clinical research in this field has also expanded substantially in China. ...
07
DOI 10.1177/10430342261488959
Open DOI
Practical Considerations for Gene and Cell Therapy Delivery in Temporal Lobe Epilepsy and Other Neurological Disorders
Biological cell and gene approaches have great potential to provide durable, disease-modifying therapies for, as yet, incurable neurological disorders. The central nervous system (CNS), unlike other organ systems, however, poses unique c...
08
DOI 10.1177/10430342261490708
Open DOI
uniQure Submits U.S., U.K. Applications for Huntington’s Disease Candidate
09
DOI 10.1177/10430342261487919
Open DOI
Development of a Recombinant Adeno-Associated Virus Vector for Human T Lymphocyte- and Natural Killer Cell-Targeted Gene Therapy
Recombinant adeno-associated virus (rAAV) vectors are widely used for gene delivery but show limited efficiency in immune cells, including T lymphocytes and natural killer (NK) cells. To overcome this barrier, we have developed a CD7-tar...
10
DOI 10.1177/10430342261486117
Open DOI
Development of an AAV-Encoded Adenine Base Editor for Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a devastating X-linked disorder caused by out-of-frame mutations in the DMD gene, most commonly large deletions or duplications, as well as nonsense and splice site mutations, that result in the absen...
Bibliographical & Catalog Notes
Also issued online.
Complemented by: Human gene therapy. Clinical development.
19950524 Not printed on acid-free paper